Glycopyrronium Bromide

Phase 2Small molecule

Novartis

Glycopyrronium Bromide is one of 61 small molecule programs targeting Hyperhidrosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperhidrosisActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

AsthmaActive, not recruiting

HyperhidrosisPhase 2

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

35 2

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 3

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 4

Glycopyrronium Bromide

Novartis

Phase 2

1 5

Formoterol Fumarate

AstraZeneca

Preclinical

8 6

Aciphex

Akero Therapeutics

Preclinical

2 7

Paracetamol

GSK

Preclinical

1 8

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

2 9

Ozone

TTanta University

Preclinical

1 10

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Asthma

NCT05222529

Clinical

Trials by Indication[1]

Efficacy2 trials

A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo

Completed· Novartis logo

Novartis·Phase 3·NCT01005901·1,324 enrolled

A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD

Completed· Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.·Phase 3·NCT04320342·3,433 enrolled

Chronic Obstructive Pulmonary Disease2 trials

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

Completed· Novartis logo

Novartis·Phase 3·NCT00929110·1,066 enrolled

Dose Ranging Study of Glycopyrronium Bromide in Patients With Moderate or Severe Chronic Obstructive Pulmonary Disease

Completed·PProsonix Limited·Phase 2·NCT01703624·37 enrolled

Ventilation1 trial

Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD Patients

Completed·UUniversity of Milan·Phase 4·NCT02181023·37 enrolled

Asthma1 trial

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma

Recruiting· Novartis logo

Novartis·Phase 2·NCT05222529·42 enrolled

Hyperhidrosis1 trial

Assessment of Safety, Tolerability, Systemic Exposure and Efficacy of GPB Cream in Adolescents With Severe Primary Hyperhidrosis

Completed·—·Phase 2·NCT05863104·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Glycopyrronium Bromide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Glycopyrronium Bromide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Glycopyrronium Bromide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

Glycopyrronium Bromide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Efficacy2 trials

Chronic Obstructive Pulmonary Disease2 trials

Ventilation1 trial

Asthma1 trial

Hyperhidrosis1 trial

References

Drug Info

Quick Facts

Related News